330 related articles for article (PubMed ID: 19318626)
1. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
2. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
3. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Brower V
J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
[No Abstract] [Full Text] [Related]
4. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab faces trials, clinical and otherwise.
Tuma RS
J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
[No Abstract] [Full Text] [Related]
6. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
7. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
8. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
9. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
10. Trastuzumab cardiac side effects: only time will tell.
Levine MN
J Clin Oncol; 2005 Nov; 23(31):7775-6. PubMed ID: 16258081
[No Abstract] [Full Text] [Related]
11. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
13. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
14. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
Gianni L
Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
[No Abstract] [Full Text] [Related]
15. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.
Tuma R
J Natl Cancer Inst; 2008 Apr; 100(7):459-61. PubMed ID: 18364497
[No Abstract] [Full Text] [Related]
16. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
17. [Two cases with have a complication in cardiac function during chemotherapy with trastuzumab].
Ishizaki A; Katayama K; Negishi T; Kamisaka K
Gan To Kagaku Ryoho; 2007 Apr; 34(4):639-41. PubMed ID: 17431357
[TBL] [Abstract][Full Text] [Related]
18. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
19. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
20. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
Morris PG; Hudis CA
Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
[No Abstract] [Full Text] [Related]
[Next] [New Search]